Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
Wake County is under alert.
Program
On WRAL at 11: Storms rolling through Sunday night. We'll tell you if they'll affect your Labor Day plans in the morning
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
120.89
+0.47 (+0.39%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Pot Stocks Down In June - Remain +29.6% YTD
July 04, 2021
There are four cannabis/cannabis-related pot stock categories which I use to provide the clearest overview of the cannabis stock sector that is available anywhere. Below is a comparison of how each...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
July 01, 2021
Novartis AG (NYSE: NVS) could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper...
Via
Benzinga
Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut
June 30, 2021
Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company ...
Via
Benzinga
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
June 29, 2021
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Is This Chinese Biopharma Stock Still a Buy?
June 28, 2021
The pharmaceutical company had a solid first quarter and boasts a nice pipeline.
Via
The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
June 26, 2021
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Crazy Thursday
June 24, 2021
Today the US stock market went ballistic probably because of a higher joblessness level than expected.
Via
Talk Markets
Reconsidered Boom
June 22, 2021
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded.
Via
Talk Markets
The First Day Of Summer And Prime Day
June 21, 2021
The bull is back in business today.
Via
Talk Markets
Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients
June 21, 2021
Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for...
Via
Benzinga
Continued Uncertainty
June 15, 2021
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all.
Via
Talk Markets
Dreary Day
June 14, 2021
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold.
Via
Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
June 14, 2021
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Wednesday News And Catch-Up
June 09, 2021
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
FDA surprise
June 07, 2021
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year.
Via
Talk Markets
Exposures
Product Safety
Novartis's Iptacopan Aces Mid-Stage Kidney Disease Trial
June 07, 2021
Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-...
Via
Benzinga
A Better Switch
June 04, 2021
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase.
Via
Talk Markets
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Exposures
Product Safety
Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival
June 04, 2021
Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide...
Via
Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
June 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,...
Via
Benzinga
Fan Hit
June 03, 2021
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares.
Via
Talk Markets
Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
June 03, 2021
Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC...
Via
Benzinga
This Genetics Stock Could Have a Bright Future
June 03, 2021
Here's one genetics play that you might want to put on your radar.
Via
The Motley Fool
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
June 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis
June 02, 2021
Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of...
Via
Benzinga
Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients
June 02, 2021
The FDA has approved Novartis AG’s (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older...
Via
Benzinga
Exposures
Product Safety
A Catch-Up Day
June 01, 2021
OPEC had a virtual meeting about rising demand for oil and rising demand that oil companies cut their carbon footprint.
Via
Talk Markets
Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety
June 01, 2021
Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after...
Via
Benzinga
More Inflationary Pressures
May 28, 2021
Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%.
Via
Talk Markets
New New Deal Worries
May 27, 2021
Nio is up 1.4% today on another round of Meme buying.
Via
Talk Markets
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.